A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination With Filgrastim in Early Recovery Post-Myocardial Infarction
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Apr 2018
At a glance
- Drugs Dutogliptin (Primary) ; Filgrastim
- Indications Myocardial infarction
- Focus Adverse reactions
- Sponsors RECARDIO
- 31 Jan 2018 Planned initiation date changed from 1 Apr 2016 to 1 Apr 2018, according to a Recardio media release.
- 31 Jan 2018 Status changed from planning to not yet recruiting, according to a Recardio media release.
- 31 Jan 2018 According to a Recardio media release, company received the FDA approval for this study and plans to initiate patients enrollment in Q2 2018.